What is Engeneic?
Engeneic is a biotechnology firm dedicated to the research, development, and manufacturing of targeted anti-cancer therapies. At the core of its innovation is the first-in-class EDV nanocell platform, a cyto-immunotherapy technology designed to directly target tumors while simultaneously activating the patient's immune system. The company is currently advancing its EGFR-targeted EDV nanocells through a Phase I/IIa clinical trial, evaluating their safety and efficacy in patients with advanced solid tumors. Engeneic's strategic objective is to bring its novel cancer treatments to market, aiming to enhance patient outcomes.
How much funding has Engeneic raised?
Engeneic has raised a total of $18M across 3 funding rounds:
Private Equity
$1M
Series A
$7M
Series B
$10M
Private Equity (2011): $1M, investors not publicly disclosed
Series A (2014): $7M, investors not publicly disclosed
Series B (2014): $10M supported by GRT Capital Partners LLC and Foley Ventures
Key Investors in Engeneic
GRT Capital Partners LLC
GRT Capital Partners LLC is an investment firm that likely focuses on providing capital for companies with significant growth potential, potentially within the biotechnology or healthcare sectors given Engeneic's focus.
Foley Ventures
Foley Ventures is an independent venture capital fund that invests across diverse industries including healthcare and biotechnology, supporting companies from early-stage development through to scaling.
What's next for Engeneic?
The recent major strategic investment positions Engeneic for accelerated growth and clinical development. This capital infusion is expected to fuel the progression of its EDV nanocell platform through further clinical trials and support the company's path toward commercialization. The company's focus on a first-in-class immunotherapy technology suggests a strong potential for market disruption in the oncology sector, contingent on successful clinical validation and regulatory approval.
See full Engeneic company page
